NCT05813470 - Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma | Biotech Hunter

Enrollment

256

Participants

Timeline

Start Date

January 18, 2021

Primary Completion Date

January 15, 2023

Study Completion Date

January 15, 2023

Conditions

Allergic AsthmaUncontrolled Moderate to Severe

Interventions

BIOLOGICAL

Omalizumab (CinnaGen)

Omalizumab (CinnaGen, Iran) was administered via subcutaneous injection

BIOLOGICAL

Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)

Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) was administered via subcutaneous injection

Trial Locations (22)

Golestan Hospital, Ahvāz

Imam Khomeini, Ahvāz

Khorshid Hospital, Isfahan

Dr.Tavakoul Office, Karaj

Afzaalipour Hospital, Kerman

Dr.Mirsadraei Office, Mashhad

Qaem Hospital, Mashhad

Dr.Qalebaqi Office, Rasht

Razi Hospital, Rasht

Imam Khomeini Hospital, Sari

Imam Reza Hospital, Shiraz

Imam Reza Hospital, Tabriz

Baqiatallah Hospital, Tehran

Firouzgar Hospital, Tehran

Imam Khomeini Hospital, Tehran

Jihad Academic Asthma and Allergy Clinic, Tehran

Masih Hospital, Tehran

Modares Hospital, Tehran

Rasoul Akram Hospital, Tehran

Shariati Hospital, Tehran

Sadoghi Hospital, Yazd

Valiasr Hospital, Zanjān